Hepatitis C virus/human immunodeficiency virus coinfection: Clinical management issues

Clinical Infectious Diseases

Volumn 31, Issue 1, 2000, Pages 154-161

  Poles, Michael A ^a   Dieterich, Douglas T ^b   Mayer, Kenneth H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT PLANNING; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

DISEASE MANAGEMENT; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 0034455573     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313892     Document Type: Article

References (58)

1. Impact of chronic liver disease due to hepatitis viruses as a cause of hospital admission and death in HIV-infected drug users
2. Extrapolating long-term HIV/AIDS survival in the post-HAART era
3. Reciprocal interaction between human immunode-ficiency virus and hepatitis C virus infections
4. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV)
5. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1
6. Hepatitis C virus infection in the mothers and infants cohort study
7. +T cell response in acute hepatitis C
8. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with protease inhibitors: An immune restoration disease?
9. -response to hepatitis C and severity of recurrence after liver transplantation
10. Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients
11. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region I can induce antibodies cross-reacting with a large number of viral variants
12. HCV quasi species as a mechanism of rapidly progressive liver disease in patients infected with the human immunodeficiency virus
13. High hepatitis viremia and impaired antibody response in patients co-infected with HIV
14. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy
15. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. Multicenter Hemophilia Cohort Study
16. Hepatitis C virus (HCV) RNA and human immunodeficiency virus (HIV) p24 antigen in the cryoglobulin of hemophiliacs with HIV and/or HCV infection
17. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users
18. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study
19. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection
20. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C
21. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
22. The natural history of chronic hepatitis C in haemophiliacs
23. The progression of HCV-associated liver disease in a cohort of haemophilic patients
24. Influence of human immunodeficiency virus type I infection on the natural course of chronic parenterally acquired hepatitis C
25. Human immunodeficiency virus infection modifies the natural history of chronic parenterallyacquired hepatitis C with an unusually rapid progression to cirrhosis
26. HIV nucleoside analogues: New adverse effects on mitochondria
27. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
28. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival
29. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro
30. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?
31. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection
32. Effects of double and triple antiretroviral agents on the HCV viral load in patients co-infected with HIV and HCV
33. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients co-infected with HIV
34. Nucleoside analogue hepatotoxicity in HIV-infected patients
35. Hepatotoxicity after introduction of highly active antiretroviral therapy
36. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
37. Tri-therapy for human immunodeficiency virus does not modify replication of hepatitis C in coinfected patients
38. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical findings
39. 1999 USPHS/IDSA guidelines for the prevention ofopportunisticinfections in persons infected with human immunodeficiency virus
40. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C?
41. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
42. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
43. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon-α
44. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
45. Increased prevalence of TTV in HIV infected patients
46. Treatment with recombinant α-interferon of chronic hepatitis C in anti-HIV-positive patients
47. Recombinant interferon-α for chronic hepatitis C in patients positive for antibody for human immunodeficiency virus
48. Efficacy and safety of interferon-α treatment for chronic hepatitis C in HIV-infected patients
49. Treatment of hepatitis C HIV-coinfected patients with interferon: Controlled study
50. Randomised, double-blind, placebo-controlled trial of interferon α2b with and without ribavirin for chronic hepatitis C
51. Combination treatment with interferon and ribavirin for hepatitis C in HIV co-infection patients
52. Efficacy and safety of combination therapy with interferon-α 2B and ribavirin for severe chronic hepatitis C in HIV-infected patients
53. Impact of interferon plus ribavirin combination treatment on HIV infection in hemophiliacs with chronic hepatitis C and under HAART
54. Erthyropoietin use for ribavirin/ interferon induced anemia in patients with hepatitis C
55. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: A concentration-dependent interaction
56. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro
57. PEG-interferon-α2B: Pharmacokinetics, safety, and preliminary efficacy data
58. Sustained HCV eradication after interleukin-2 therapy in patients with HIV/HCV coinfection